THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [9.1]-CMP81 ID: TIP-MED-000351

Terbutaline Sulphate IP

Active Ingredient / Scientific Identity: Terbutaline Sulphate IP • Class: Short-Acting Beta-2 Adrenergic Receptor Agonist (SABA); Rapid-Onset Bronchodilator ('Reliever')

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Terbutaline Sulphate IP ([9.1]-CMP81 | ID: TIP-MED-000351) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/9-1-cmp81-terbutaline-sulphate-ip/
Generic / Entity NameTerbutaline Sulphate IP ([9.1]-CMP81)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassShort-Acting Beta-2 Adrenergic Receptor Agonist (SABA); Rapid-Onset Bronchodilator ('Relie
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug • NLEM 2022 Core Essential Medicine
Key Warning & Review DateNo adjustment required.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • NLEM 2022 Core Essent✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Terbutaline Sulphate IP (TIP-MED-000351, Reference Code [9.1]-CMP81) is classified under Respiratory, Asthma, COPD & Allergy Medicines (Ch 09) as a Short-Acting Beta-2 Adrenergic Receptor Agonist (SABA); Rapid-Onset Bronchodilator ('Reliever'). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-7-3). Selective beta-2 agonist (Bricanyl).
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-7-3). Selective beta-2 agonist (Bricanyl).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-7-3). Selective beta-2 agonist (Bricanyl).

4. Therapeutic Indications & Evidence-Supported Uses

  • Acute relief of bronchospasm in bronchial asthma and chronic obstructive pulmonary disease (COPD)
  • Prevention of exercise-induced bronchospasm
  • Adjunctive emergency lowering of serum potassium in acute severe hyperkalaemia (via nebulized high dose)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-7-3). Selective beta-2 agonist (Bricanyl).

Administration & Meal Timing: Inhalation (preferred route via pMDI + spacer or nebulizer to maximize pulmonary selectivity and minimize systemic tremor/tachycardia).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [9.1].
Metabolism & Biotransformation:
No adjustment required.
Elimination & Renal Adjustment:
No routine adjustment for inhaled doses; monitor serum potassium with high-dose nebulization.
Hepatic Impairment Considerations:
No adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to Salbutamol or propellant excipients
  • Do NOT use oral/IV Salbutamol for uncomplicated premature labour (tocolysis) due to maternal pulmonary oedema and myocardial ischaemia risk

Key Clinical Precautions: No adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Fine skeletal muscle tremor (most common dose-limiting effect — Beta-2 receptor stimulation on skeletal muscle spindles)
  • Reflex sinus tachycardia and palpitations
  • Hypokalaemia and mild hyperglycaemia (via Beta-2 Na+/K+-ATPase activation and hepatic glycogenolysis)
Serious / Dose-Limiting Adverse Effects:
  • Paradoxical bronchospasm (rare)

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Non-selective Beta-Blockers (Propranolol, Timolol eye drops): directly antagonize Beta-2 bronchodilation and precipitate life-threatening bronchospasm
  • Loop/Thiazide Diuretics, Theophylline, Corticosteroids: additive hypokalaemia (monitor K+ in acute severe asthma)
  • MAOIs and Tricyclic Antidepressants: potentiate vascular/cardiac sympathetic effects

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [9.1].

Pharmacist Patient Counselling Points:

  • Shake the inhaler well before each puff, exhale completely, actuate while inhaling slowly and deeply over 3–5 seconds, and hold breath for 10 seconds (using a valved holding chamber/spacer improves lung deposition).
  • In asthma, rely on your controller (ICS-Formoterol); needing more than 2 SABA canisters per year indicates poorly controlled asthma requiring step-up anti-inflammatory therapy.
  • Wait 1 minute between consecutive puffs.

Storage, Stability & Dispensing Safeguards: Store below 30°C; protect pressurized canister from direct sunlight, heat, and puncture.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/9-1-cmp81-terbutaline-sulphate-ip/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.